Expectations for BioPorto Diagnostics have been high since the company launched its anticipated blockbuster product almost two years ago – the kidney injury test known as NGAL. Since then, BioPorto has worked towards solutions that would ensure broad and early market access to the test. In this regard, the first partnership on a global marketing level is now in place. This comes in the form of an informal sales partnership with Siemens Healthcare Diagnostics actively promoting BioPorto’s NGAL test, while the distribution still flows through BioPorto’s sales channels.
The agreement translates into excellent synergy in that Siemens is one of the world's largest suppliers of precisely the type of analyzers that BioPorto’s The NGAL Test™ is designed to run on. The partnership creates a win-win scenario for the companies and customers. Siemens will have access to a test that their customers demand and a strategic advantage over competitors who do not offer NGAL in their test portfolios. Siemens analyzers are widely used in hospital laboratories, which ensures that the test will be economical to implement and readily available to doctors worldwide. From BioPorto’s point of view, it is hard to think of a faster and more convenient way to reach customers.
Such an informal but bespoke partnership between a reagent supplier (BioPorto) and an instrument supplier (Siemens) is far from unique in the diagnostic industry. Introduction of a new diagnostic test is a long and tough process, and being first-to-market can be crucial.
But Siemens are not the only one who has set their sights on BioPorto’s breakthrough test. Roche Diagnostics also confirmed their interest in NGAL and BioPorto continues to discuss possibilities for collaboration with more leading diagnostic companies.
About NGAL – the acute kidney injury test
Every year about 13 million people suffer from acute kidney injury of which about 4 million die.
Despite this, progress in diagnosing kidney injury has been stagnant the past 60 years.
The current methods provide the first signal of kidney failure one to three days after the kidney has been damaged. NGAL on the other hand, can detect instantaneous damage, thus giving the physician an opportunity to make crucial decisions before kidney damage evolves into a potentially fatal kidney failure. Furthermore, cost-benefit analyses show that NGAL measurements will contribute towards cost-savings for hospitals when managing kidney injury-patients.
Thea Olesen, CEO, BioPorto
Telephone +45 45 29 00 00; e-mail email@example.com
BioPorto Diagnostics A/S is an in-vitro diagnostics company that provides healthcare professionals in clinical and research settings a range of diagnostic tests and antibodies. Our pioneering product portfolio includes assays for underserved disease states such as NGAL for acute kidney injury. We sell our products in more than 80 countries through diverse sales channels and partners. BioPorto has its headquarters in Copenhagen, Denmark and is listed on the NASDAQ OMX Copenhagen stock exchange.
BioPorto A/S Logo